Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Elite Pharmaceuticals Inc. (ELTP : OTC)

• Company Description    Elite Pharmaceuticals, Inc. primarily engages in researching, developing, licensing, manufacturing, and marketing proprietary drug delivery systems and products. Their drug delivery technology involves releasing a drug into the bloodstream or delivering it to a target site in the body over an extended period of time or at predetermined times. Number of Employees: 65

• Price / Volume Information    Yesterday's Closing Price: $0.26 Daily Weekly Monthly 20 Day Moving Average: 1,162,512 shares Shares Outstanding: 1,077.14 (millions) Market Capitalization: $277.90 (millions) Beta: 0.37 52 Week High: $0.71 52 Week Low: $0.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -28.35% -28.03% 12 Week -29.80% -31.29% Year To Date -47.38% -53.33%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 165 LUDLOW AVENUE - NORTHVALE,NJ 07647 USA ph: 201-750-2646 fax: 201-750-2755 dianne@elitepharma.com http://www.elitepharma.com

• General Corporate Information    Officers Nasrat Hakim - Chief Executive Officer; President and Chairman of Carter Ward - Chief Financial Officer Barry Dash - Director Jeffrey Whitnell - Director Davis Caskey - Director Peer Information Elite Pharmaceuticals Inc. (GSAC) Elite Pharmaceuticals Inc. (CASIF) Elite Pharmaceuticals Inc. (ALCD.) Elite Pharmaceuticals Inc. (OMNN) Elite Pharmaceuticals Inc. (CGPI.) Elite Pharmaceuticals Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 28659T200 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/13/26 Share - Related Items Shares Outstanding: 1,077.14 Most Recent Split Date: (:1) Beta: 0.37 Market Capitalization: $277.90 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 12.90 PEG Ratio: - Price Ratios Price/Book: 2.65 Price/Cash Flow: 9.66 Price / Sales: 1.97 EPS Growth vs. Year Ago Period: 200.00% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -19.54% vs. Previous Quarter: -20.60% ROE 06/30/26 - 44.58 03/31/26 - 37.06 12/31/25 - 47.93 ROA 06/30/26 - 29.54 03/31/26 - 21.67 12/31/25 - 25.81 Current Ratio 06/30/26 - 3.76 03/31/26 - 6.45 12/31/25 - 7.34 Quick Ratio 06/30/26 - 2.97 03/31/26 - 5.22 12/31/25 - 5.44 Operating Margin 06/30/26 - 27.32 03/31/26 - 17.95 12/31/25 - 20.79 Net Margin 06/30/26 - 40.19 03/31/26 - 30.14 12/31/25 - 30.98 Pre-Tax Margin 06/30/26 - 46.16 03/31/26 - 38.16 12/31/25 - 39.42 Book Value 06/30/26 - 0.10 03/31/26 - 0.09 12/31/25 - 0.07 Inventory Turnover 06/30/26 - 3.59 03/31/26 - 3.52 12/31/25 - 3.48 Debt-to-Equity 06/30/26 - 0.03 03/31/26 - 0.04 12/31/25 - 0.05 Debt-to-Capital 06/30/26 - 3.26 03/31/26 - 3.57 12/31/25 - 4.50

Powered by Zacks Investment Research ©